Anidulafungin in Treating Immunocompromised Children With Neutropenia

Completed · Phase 1/Phase 2

Conditions studied: Infection, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific

In brief

RATIONALE: Anidulafungin may be effective in preventing fungal infections in immunocompromised children who have neutropenia. PURPOSE: This phase I/II trial is studying the side effects of anidulafungin and to see how well it works in preventing fungal infections in immunocompromised children with neutropenia caused by chemotherapy or aplastic anemia.

Key facts

Study ID

NCT00068471

Run by

National Cancer Institute (NCI)

Starts

2003-07-01

Expected to finish

2007-10-01

Last updated by the study team

2013-06-19

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Lombardi Cancer Center at Georgetown University Medical Center — Washington D.C., District of Columbia, United States
• Children's National Medical Center — Washington D.C., District of Columbia, United States
• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
• Duke Comprehensive Cancer Center — Durham, North Carolina, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.